Systematic review of patient-reported outcome item libraries in cancer research: an EORTC QLG study
A partir d'une revue systématique de la littérature publiée entre 2021 et 2025 (78 études), cette étude analyse, dans la recherche en oncologie, l'utilisation de bibliothèques et de listes de résultats de soins déclarés par les patients
Background: Patient reported outcome (PRO) item libraries support flexible PRO assessment in cancer research by facilitating the development of customized item lists. However, little is known about the use of item lists in clinical research. This systematic review addresses this by assessing utilization of PRO item libraries and lists in oncology research.
Methods: Systematic review of MEDLINE, Embase and CINAHL identified cancer studies using PRO item libraries to develop item lists, regardless of study design, published between October 2021-September 2025. Key features of item library usage were extracted and analyzed descriptively.
Results: Seventy-eight studies were included (25 trials/feasibility; 53 observational). The Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events system was frequently used (49/78) and symptom assessment was the most common application (63/78). Item lists were implemented across different settings including novel treatments (19/78) and rare cancers (15/78). Most item lists were derived from a single PRO item library (72/78). In some studies, there was additional customization such as item wording changes (5/78), or addition of items adapted from the item library (9/78). Item selection methods included, literature (32/78), patient involvement (8/33) and consultation with healthcare professionals (11/78). Many studies (40/78) did not report methods used.
Conclusions: PRO item libraries are increasingly used to create customized item lists in oncology research, primarily for symptom assessment. However, reporting practices for methods used are inconsistent, highlighting the need for standardized guidelines for reporting PRO item lists in clinical trials and routine care to improve transparency, reproducibility, and quality.
Journal of the National Cancer Institute , résumé, 2026